Atara Biotherapeutics Stock Soars After FDA Green Light for Cancer Therapy
Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.
/ 2 items
Atara stock jumps 52% after FDA signals its cancer therapy may get approved, boosting hope for patients and investors.
Atara Biotherapeutics (ATRA) receives second FDA rejection for EBVALLO cancer therapy despite resolving manufacturing issues, citing concerns about clinical trial design.